A cost-minimization analysis of combination therapy in hypertension: fixed-dose vs extemporary combinations

Marco Bellone, Pierluigi Sbarra

DOI: https://doi.org/10.7175/fe.v14i4.886

Abstract

BACKGROUND: Cardiovascular disease management and prevention represent the leading cost driver in Italian healthcare expenditure. In order to reach the target blood pressure, a large majority of patients require simultaneous administration of multiple antihypertensive agents.
OBJECTIVE: To assess the economic impact of the use of fixed dose combinations of antihypertensive agents, compared to the extemporary combination of the same principles.
METHODS: A cost minimization analysis was conducted to determine the pharmaceutical daily cost of five fixed dose combinations (olmesartan 20 mg + amlodipine 5 mg, perindopril 5 mg + amlodipine 5 mg, enalapril 20 mg + lercanidipine 10 mg, felodipine 5 mg + ramipril 5 mg, and delapril 30 mg + manidipine 10 mg) compared with extemporary combination of the same principles in the perspective of the Italian NHS. Daily acquisition costs are estimated based on current Italian prices and tariffs.
RESULTS: In three cases the use of fixed‑dose combination instead of extemporary combination induces a lower daily cost. Fixed combination treatment with delapril 30 mg + manidipine 10 mg induces greater cost savings for the National Health System (95,47 €/pts/year), as compared to free drugs combination therapy.
CONCLUSIONS: Compared with free drug combinations, fixed‑dose combinations of antihypertensive agents are associated with lower daily National Health Service acquisition costs.

Keywords

Hypertension, Fixed-dose combinations, Cost-minimization analysis

Full Text:

HTML PDF

References

  • World Health Organization. A global brief on Hypertension. World Health Day, 2013. Disponibile on line all’indirizzo http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en (ultimo accesso ottobre 2013)
  • Ministero della Salute. Tavole Rapporto SDO, 2011. Disponibile on line all’indirizzo http://www.salute.gov.it (ultimo accesso ottobre 2013)
  • ISTAT. Italia in cifre. Edizione 2012. Disponibile on line all’indirizzo http://www.istat.it/it/archivio/30329 (ultimo accesso ottobre 2013)
  • I.Stat. Disponibile on line all’indirizzo http://dati.istat.it/Index.aspx (ultimo accesso ottobre 2013)
  • Osservatorio Epidemiologico Cardiovascolare (OEC). Disponibile on line all’indirizzo http://www.cuore.iss.it/fattori/distribuzione.asp (ultimo accesso ottobre 2013)
  • Banca dati ISTAT. Popolazione Residente per età, sesso e stato civile al 1° gennaio Anno 2012. Disponibile on line all’indirizzo http://demo.istat.it/pop2012/index.html (ultimo accesso ottobre 2013)
  • Zaniolo O, Pradelli L. Valutazione dell’impatto sul budget del Sistema Sanitario Nazionale dell’utilizzo di aliskiren nel trattamento dell’ipertensione. Farmeconomia e percorsi terapeutici 2009; 10: 5-18
  • Volpe M, Rosei EA, Ambrosioni E, et al. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev 2013; 20: 45-52; http://dx.doi.org/10.1007/s40292-013-0007-2
  • Tocci G, Rosei EA, Ambrosioni E, et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens 2012; 30: 1065-74; http://dx.doi.org/10.1097/HJH.0b013e3283535993
  • Mancia G, Fagard R, Narkiewicz K, et al.; The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1925-38; http://dx.doi.org/10.1097/HJH.0b013e328364ca4c
  • Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J 2011; 32: 2499-506; http://dx.doi.org/10.1093/eurheartj/ehr177
  • Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906; http://dx.doi.org/10.1016/S0140-6736(05)67185-1
  • Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28; http://dx.doi.org/10.1056/NEJMoa0806182
  • Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31; http://dx.doi.org/10.1016/S0140-6736(04)16451-9
  • Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407; http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.139816
  • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52; http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2
  • Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2008; 10: 751-60; http://dx.doi.org/10.1111/j.1751-7176.2008.00015.x
  • Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427; http://dx.doi.org/10.1136/bmj.326.7404.1427
  • Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356: 1955-64; http://dx.doi.org/10.1016/S0140-6736(00)03307-9
  • Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4: 90-8; http://dx.doi.org/10.1016/j.jash.2010.03.001
  • Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009; 11: 376-82; http://dx.doi.org/10.1111/j.1751-7176.2009.00138.x
  • Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010; 26: 2877-87; http://dx.doi.org/10.1185/03007995.2010.534129
  • Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9; http://dx.doi.org/10.1016/j.amjmed.2006.08.033
  • Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190-6; http://dx.doi.org/10.1016/j.amjhyper.2006.04.006
  • OsMed. Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia – Rapporto Nazionale 2012. Disponibile on line all’indirizzo: http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdf (ultimo acceso ottobre 2013)
  • IMS Health. Dati forniti da Bracco e aggiornati al 30 giugno 2013
  • Eandi M, Pradelli L, Zaniolo O. Farmacoeconomia: principi di base. Torino: SEEd, 2006
  • Codifa. La banca dati de L’informatore farmaceutico (ultimo accesso ottobre 2013)
  • Liste di trasparenza dei medicinali inseriti nell’elenco dei farmaci equivalenti (Legge 178/2002) con i relativi prezzi di riferimento aggiornati al 15 ottobre 2013
  • D.L. n.78 del 31 maggio 2010 (G.U. n.125 del 31 maggio 2010) coordinato con la legge di conversione n. 122 del 30 luglio 2010 (G.U. n.176 del 30/07/2010, recante: Misure urgenti in materia di stabilizzazione finanziaria e di competitività economica
  • Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care 2001; 39: 599-615; http://dx.doi.org/10.1097/00005650-200106000-00008
  • Hansson L, Lloyd A, Anderson P, et al. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002; 11: 35-45; http://dx.doi.org/10.1080/080370502753543945
  • Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-30; http://dx.doi.org/10.1097/01.mlr.0000163641.86870.af

Refbacks

  • There are currently no refbacks.




© SEEd srl